NCT04780217View on ClinicalTrials.gov

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

August 31, 2025

Conditions
Solid TumorHepatocellular CarcinomaColorectal CancerNSCLCOvarian CancerEndometrial Cancer
Interventions
BIOLOGICAL

T3011

T3011 will be administered through IV drip or pumping.

Trial Locations (6)

29601

Prisma Health - Upstate, Greenville

29605

Virginia Cancer Specialists, Greenville

33322

BRCR Medical Center Inc, Plantation

37203

Sarah Cannon Research Institute, Nashville

75230

Mary Crowley Cancer Research, Dallas

85012

Banner MD Anderson Cancer Center, Phoenix

All Listed Sponsors
lead

ImmVira Pharma Co. Ltd

INDUSTRY